# Systemic Antibacterial and Antifungal Drugs:  Susceptibility Test Interpretive Criteria Labeling for NDAs and ANDAs - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/systemic-antibacterial-and-antifungal-drugs-susceptibility-test-interpretive-criteria-labeling-for-ndas-and-andas/a071fec6-d1c9-41d8-bbbf-4f71788c7e7f

> FDA guidance document: Systemic Antibacterial and Antifungal Drugs:  Susceptibility Test Interpretive Criteria Labeling for NDAs and ANDAs. Issue date: December 13, 2017. Get complete insights and analysis.

---

## Details

- Title: Systemic Antibacterial and Antifungal Drugs:  Susceptibility Test Interpretive Criteria Labeling for NDAs and ANDAs
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2017-12-13
- Last Changed: 2020-05-05
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2017-N-5925">FDA-2017-N-5925</a>

## Related Documents

- [Allergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/allergic-rhinitis-developing-drug-products-for-treatment-guidance-for-industry/dcca7128-d84a-436f-83a2-e705904c701f)
- [Recurrent Herpes Labialis:  Developing Drugs for Treatment and Prevention](https://www.globalkeysolutions.net/guidances/guidance-document/recurrent-herpes-labialis-developing-drugs-for-treatment-and-prevention/e4e0fd38-d19b-43b7-9f6b-13b91c093857)
- [Migraine: Developing Drugs for Acute Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/migraine-developing-drugs-for-acute-treatment/39ba4b4b-6c93-4849-a087-866c6bf4edff)